Safety, Activity Seen with Frontline Zanidatamab Plus Chemo ± Bevacizumab in HER2+ mCRC
Zanidatamab (ZW25) plus mFOLFOX6-2 with or without bevacizumab showed 83.3% and 100% confirmed overall response rates, respectively, in a phase 2 study for HER2-positive mCRC, with manageable safety profile and no treatment-related deaths.
Related Clinical Trials
Reference News
Safety, Activity Seen with Frontline Zanidatamab Plus Chemo ± Bevacizumab in HER2+ mCRC
Zanidatamab (ZW25) plus mFOLFOX6-2 with or without bevacizumab showed 83.3% and 100% confirmed overall response rates, respectively, in a phase 2 study for HER2-positive mCRC, with manageable safety profile and no treatment-related deaths.